Merck (NYSE:MRK) announced a major reorganization of its Human Health business into two global units focused on Oncology and on Specialty, Pharma & Infectious Diseases. The company named new senior ...

Merck (MRK) announced on Wednesday that its single-tablet antiviral regimen, doravirine and islatravir for adults with HIV, was found to be non-inferior to Gilead’s (GILD) once-daily HIV pill Biktarvy ...

RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that new data from its research pipeline for HIV prevention and treatment will ...

Merck MRK recently launched two late-stage clinical studies to evaluate MK-8527, its investigational once-monthly oral pill for HIV pre-exposure prophylaxis (PrEP). The EXPrESSIVE-11 study, which ...

Merck Announces Positive Topline Results from the Pivotal Phase 3 Trial Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir (DOR/ISL) in ...

Merck (NYSE:MRK) reported a series of positive late stage clinical trial results for oncology and HIV therapies, including new Phase 3 data for KEYTRUDA and WELIREG regimens in kidney, ovarian, and ...

A Phase III switch study occurring over 96 weeks has demonstrated that US pharma giant Merck & Co’s doravirine/islatravir (DOR/ISL) sustains durable viral suppression with stable safety outcomes in ...

TRENTON, N.J. (AP) -- Drugmaker Merck & Co., a pioneer in AIDS research, is licensing two experimental HIV drugs from other companies and advancing one of its own into mid-stage patient testing. Merck ...

Merck (NYSE:MRK) is approaching phase 2 data for Winrevair in pulmonary hypertension. Results will focus on the 6 minute walk ...

Investigational DOR/ISL is the first non-INSTI, two-drug regimen to demonstrate non-inferiority to BIC/FTC/TAF in a Phase 3 clinical trial in treatment-naïve adults with HIV-1 infection The company is ...